Idorsia forms research collaboration with Roche in the field of cancer immunotherapy

Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)

Idorsia announces financial results as of 30 September 2017

Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company

ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

Idorsia - Reaching out for more